Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
420
Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.
A structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
RECRUITINGFujian Provincial Hospital, Affiliated to Fuzhou University
Fuzhou, Fujian, China
RECRUITINGThe First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
RECRUITINGZhongnan Hospital of Wuhan University
Wuhan, Hubei, China
RECRUITINGNanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
RECRUITINGThe Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University
Suzhou, Jiangsu, China
RECRUITINGHuadong Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGRenji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGShanghai Tenth People's Hospital, School of Medicine, Tongji University
Shanghai, Shanghai Municipality, China
RECRUITINGZhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITING...and 3 more locations
Percentage change of body weight
Time frame: From randomization to Week 52
Change in body mass index (BMI)
Time frame: From randomization to Week 52
Change in waist circumference
Time frame: From randomization to Week 52
Change in total body fat
Time frame: From randomization to Week 52
Change in abdominal visceral fat area
Abdominal visceral fat area is quantified by CT scan
Time frame: From randomization to Week 52
Change in hepatic fat content
Hepatic fat content is quantified by controlled attenuation parameter (CAP), measured by Fibroscan.
Time frame: From randomization to Week 52
Change in blood pressure
Time frame: From randomization to Week 52
Change in serum lipid profile
Time frame: From randomization to Week 52
Changes in blood glucose
Time frame: From randomization to Week 52
Changes in insulin sensitivity
Insulin sensitivity is assessed by HOMA-IR index
Time frame: From randomization to Week 52
Changes in pancreatic β-cell function
Pancreatic β-cell function is assessed by HOMA-β index
Time frame: From randomization to Week 52
Change in pulse wave velocity (PWV)
Time frame: From randomization to Week 52
Quality of sleep measured by the Pittsburgh sleep quality index (PSQI)
Time frame: From randomization to Week 52
Quality of life measured by the 12-item Short-Form Health Survey Questionnaire (SF-12)
Time frame: From randomization to Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.